UY34753A - Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro - Google Patents

Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro

Info

Publication number
UY34753A
UY34753A UY0001034753A UY34753A UY34753A UY 34753 A UY34753 A UY 34753A UY 0001034753 A UY0001034753 A UY 0001034753A UY 34753 A UY34753 A UY 34753A UY 34753 A UY34753 A UY 34753A
Authority
UY
Uruguay
Prior art keywords
chloride content
anamoreline
chlorhydrate
produce
methods
Prior art date
Application number
UY0001034753A
Other languages
English (en)
Spanish (es)
Inventor
Shin-Itsu Kuwabe
Yanagimachi Takehiko
Yoshiyama Hideyuki
Pines Seemon
Eleanor De Groot
Silvina Garcia Rubio
Manini Peter
Original Assignee
Helsinn Healthcare Sa
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34753(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa, Ono Pharmaceutical Co filed Critical Helsinn Healthcare Sa
Publication of UY34753A publication Critical patent/UY34753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
UY0001034753A 2012-04-20 2013-04-19 Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro UY34753A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
UY34753A true UY34753A (es) 2013-11-29

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034753A UY34753A (es) 2012-04-20 2013-04-19 Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro

Country Status (48)

Country Link
US (8) US20140018391A1 (enExample)
EP (3) EP3517532B1 (enExample)
JP (3) JP6109925B2 (enExample)
KR (2) KR102141323B1 (enExample)
CN (3) CN110041304A (enExample)
AP (1) AP2014008013A0 (enExample)
AR (1) AR090725A1 (enExample)
AU (1) AU2013249197B2 (enExample)
BR (1) BR112014025972A8 (enExample)
CA (2) CA2869893C (enExample)
CL (1) CL2014002817A1 (enExample)
CO (1) CO7131356A2 (enExample)
CR (1) CR20140530A (enExample)
CY (1) CY1120276T1 (enExample)
DK (2) DK3517532T3 (enExample)
DO (1) DOP2014000235A (enExample)
EA (1) EA031581B1 (enExample)
EC (1) ECSP14027739A (enExample)
ES (2) ES2820354T3 (enExample)
GE (2) GEP20186902B (enExample)
HK (1) HK1248694A1 (enExample)
HR (1) HRP20180316T1 (enExample)
HU (2) HUE035697T2 (enExample)
IL (1) IL235064B (enExample)
JO (1) JO3353B1 (enExample)
LT (1) LT2838892T (enExample)
MA (1) MA37524B1 (enExample)
MD (1) MD4615C1 (enExample)
ME (1) ME02966B (enExample)
MX (1) MX354793B (enExample)
MY (1) MY170068A (enExample)
NI (1) NI201400124A (enExample)
NO (1) NO2877697T3 (enExample)
NZ (1) NZ700833A (enExample)
PE (1) PE20150084A1 (enExample)
PH (1) PH12014502351B1 (enExample)
PL (2) PL2838892T3 (enExample)
PT (2) PT2838892T (enExample)
PY (1) PY1316881A (enExample)
RS (1) RS56869B1 (enExample)
SG (2) SG11201406478XA (enExample)
SI (2) SI2838892T1 (enExample)
TN (1) TN2014000421A1 (enExample)
TW (2) TWI677494B (enExample)
UA (1) UA116207C2 (enExample)
UY (1) UY34753A (enExample)
WO (1) WO2013158874A1 (enExample)
ZA (1) ZA201408508B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료
PE20180928A1 (es) 2015-07-24 2018-06-08 Newlink Genetics Corp Sales y profarmacos de 1-metil-d-triptofano
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
JP7854809B2 (ja) * 2019-08-30 2026-05-07 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
WO2005030698A1 (en) * 2003-09-26 2005-04-07 Ranbaxy Laboratories Limited Process for the preparation of voglibose
EP2298760B1 (en) 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
NZ700833A (en) 2016-01-29
PL2838892T3 (pl) 2018-05-30
US9956261B2 (en) 2018-05-01
WO2013158874A1 (en) 2013-10-24
ME02966B (me) 2018-07-20
US10576122B2 (en) 2020-03-03
BR112014025972A2 (pt) 2017-06-27
CA2869893C (en) 2019-03-05
SG10201608488RA (en) 2016-12-29
AR090725A1 (es) 2014-12-03
US20190000914A1 (en) 2019-01-03
EA031581B1 (ru) 2019-01-31
CR20140530A (es) 2015-03-25
HK1202863A1 (en) 2015-10-09
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
GEP20186902B (en) 2018-10-25
HRP20180316T1 (hr) 2018-04-06
KR20150013115A (ko) 2015-02-04
US9872883B2 (en) 2018-01-23
UA116207C2 (uk) 2018-02-26
CA3031652A1 (en) 2013-10-24
SI2838892T1 (en) 2018-05-31
JP2018076375A (ja) 2018-05-17
US20140018391A1 (en) 2014-01-16
PL3290410T3 (pl) 2021-01-11
US20150072934A1 (en) 2015-03-12
JP2015514779A (ja) 2015-05-21
MX2014012178A (es) 2015-08-05
CY1120276T1 (el) 2019-07-10
CL2014002817A1 (es) 2015-08-14
SI3290410T1 (sl) 2020-11-30
CN103857669A (zh) 2014-06-11
PT2838892T (pt) 2018-02-28
MY170068A (en) 2019-07-03
US10300105B2 (en) 2019-05-28
NO2877697T3 (enExample) 2018-10-13
JO3353B1 (ar) 2019-03-13
MX354793B (es) 2018-03-21
CA3031652C (en) 2020-10-27
IL235064A0 (en) 2014-12-31
KR20190044697A (ko) 2019-04-30
US20200276259A1 (en) 2020-09-03
TW201348224A (zh) 2013-12-01
US9981002B2 (en) 2018-05-29
LT2838892T (lt) 2018-03-12
ES2820354T3 (es) 2021-04-20
EP2838892B1 (en) 2017-12-06
US20160229889A1 (en) 2016-08-11
AP2014008013A0 (en) 2014-10-31
SG11201406478XA (en) 2014-11-27
PE20150084A1 (es) 2015-01-23
US9403867B2 (en) 2016-08-02
EP3517532A1 (en) 2019-07-31
ECSP14027739A (es) 2015-12-31
TW201722928A (zh) 2017-07-01
MA37524A1 (fr) 2016-06-30
TWI677494B (zh) 2019-11-21
TWI589572B (zh) 2017-07-01
US10905737B2 (en) 2021-02-02
PY1316881A (es) 2016-06-01
EP3290410B1 (en) 2020-07-01
GEAP201813634A (en) 2018-06-25
AU2013249197A1 (en) 2014-10-30
CN110041398A (zh) 2019-07-23
HK1248694A1 (en) 2018-10-19
JP6109925B2 (ja) 2017-04-05
NI201400124A (es) 2015-09-21
MA37524B1 (fr) 2017-04-28
DK2838892T3 (en) 2018-03-12
PT3517532T (pt) 2021-11-08
RS56869B1 (sr) 2018-04-30
PH12014502351A1 (en) 2015-01-12
BR112014025972A8 (pt) 2021-06-22
JP6616853B2 (ja) 2019-12-04
HUE035697T2 (en) 2018-05-28
CA2869893A1 (en) 2013-10-24
EA201401151A1 (ru) 2015-06-30
MD4615C1 (ro) 2019-08-31
KR101972998B1 (ko) 2019-04-29
JP6284665B2 (ja) 2018-02-28
DK3517532T3 (da) 2022-01-03
MD20140122A2 (ro) 2015-05-31
US20160237115A1 (en) 2016-08-18
US20190231843A1 (en) 2019-08-01
US20160235804A1 (en) 2016-08-18
KR102141323B1 (ko) 2020-08-05
CN110041304A (zh) 2019-07-23
JP2017101082A (ja) 2017-06-08
PH12014502351B1 (en) 2015-01-12
HUE050865T2 (hu) 2021-01-28
CO7131356A2 (es) 2014-12-01
CN103857669B (zh) 2019-06-28
EP2838892A1 (en) 2015-02-25
EP3517532B1 (en) 2021-10-13
TN2014000421A1 (en) 2016-03-30
AU2013249197B2 (en) 2017-04-06
ES2658862T3 (es) 2018-03-12
EP3290410A1 (en) 2018-03-07
IL235064B (en) 2019-09-26
DOP2014000235A (es) 2015-01-31

Similar Documents

Publication Publication Date Title
RS67779B1 (sr) Farmaceutska kompozicija, postupci za lečenje i njihova primena
UA117011C2 (uk) Фармацевтичний склад омекамтиву мекарбілу і спосіб його застосування
HUE055044T2 (hu) MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
IL244597A0 (en) Replication suppressors of influenza viruses, preparations containing them and their uses
HUE060743T2 (hu) Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
IL245585A0 (en) Compounds that suppress the reproduction of influenza viruses, preparations containing them and their uses
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
PT3069720T (pt) Composição farmacológica que contém derivados de glutarimida, e a aplicação da mesma no tratamento de doenças eosinofílicas
MX2016006916A (es) Composicion farmaceutica, que comprende particulas de aglutinante de fosfato.
IN2013MU03641A (enExample)
EP3003344A4 (en) CONOTOXINPEPTIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
CR20140530A (es) Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
IL238851A0 (en) The history of pyrrolidine, pharmaceutical preparations and their uses
FI20135683L (fi) Saostettua kalsiumkarbonaattia sisältävä koostumus, menetelmä sen valmistamiseksi sekä sen käytöt
TWI562776B (en) Pharmaceutical composition and uses thereof
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
SG11201601921RA (en) Azeotrope-like compositions of fo-e-1,3,4,4,4-pentafluoro-3-trifluoromethyl-1-butene and e-1-chloro-3,3,3-trifluoropropene and uses thereof
EP2717862A4 (en) COMPOSITIONS FOR ENCAPSULATION OF BIOMATERIALS AND USES THEREOF
PL2956129T3 (pl) Kompozycje farmaceutyczne zawierające deksketoprofen i tramadol
IN2013MU02715A (enExample)

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20220927